Corcept Therapeutics Inc
CORT
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.21B
Close$
$86.14
27.1% downside
Current Fair Value
27.1% downsideOvervalued by 27.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.21 Billion |
|---|---|
| Enterprise Value | $13.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.95 |
| Beta | 0.46 |
| Outstanding Shares | 105,377,000 |
Return
| Return on Equity | 7.73% |
|---|---|
| Return on Assets | 6.14% |
| Return on Invested Capital | 2.92% |
Valuation & Multiples
| P/E Ratio | 235.1 |
|---|---|
| PEG | 1080.6 |
| Price to Sales | 16.87 |
| Price to Book Ratio | 19.68 |
| Enterprise Value to Revenue | 15.8 |
| Enterprise Value to EBIT | 611.13 |
| Enterprise Value to Net Income | 240 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$219.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.65
Average shareholder expectationRevenue Estimate
$320.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2663▼ 181.10% |
|---|---|
| Total Calls | 1,641,524▲ 59.79% |
| Total Puts | 437,100▼ 79.52% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 79.70%▲ 3.10% |
|---|---|
| Total Invested | $7.23B▲ 125.70% |
| Investors Holding | 442▲ 73.00% |
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...